Advancing Precision Medicine for Children with Cancer
The Ty Louis Campbell Foundation (TLC) has invested over $50,000 in the Children’s Brain Tumor Project at Weill Cornell Medicine, specifically supporting the groundbreaking research of Dr. Jeffrey Greenfield in precision medicine for children with brain tumors. Childhood cancers are rare, and each tumor is unique, which makes access to tumor tissue and genetic data absolutely essential for discovering new, effective treatments.
The Children’s Brain Tumor Project is investigating a novel approach known as N-of-1 clinical trials, designed specifically for children with brain tumors. In this model, a child’s tumor tissue can be studied outside of the patient, allowing researchers to test targeted drugs for efficacy in the lab before administering them to the child. This individualized strategy helps identify therapies that are most likely to work, minimizes exposure to ineffective treatments, and provides oncologists with data-driven guidance to make truly personalized treatment decisions.
By combining advanced tools like genetic sequencing, bioinformatics, immunophenotyping, and drug screening, researchers can tailor therapy to the molecular characteristics of each child’s tumor. TLC is proud to support this cutting-edge work, which transforms donated tumor tissue into actionable insights—and brings the promise of precision medicine closer to children fighting some of the rarest and most aggressive brain tumors.
